Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study

  • Etude concernée: IFCT-0502
  • Auteurs / Authors: Borget I, Pérol M, Pérol D, Lavolé A, Greillier L, Dô P, Westeel V, Crequit J, Léna H, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Chabaud S, Vergnenegre A, Zalcman G, Chouaïd C
  • Journal / Conference: BMC Cancer
  • Année / Year: 2014
  • PMID: 25511923
  • Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/25511923